Tomas Rajtik1, Eva Goncalvesova2, Zoltan V Varga3, Przemyslaw Leszek4, Mariusz Kusmierczyk4, Michal Hulman5, Jan Kyselovic1, Peter Ferdinandy3, Adriana Adameova1. 1. Department of Pharmacology & Toxicology, Faculty of Pharmacy, Comenius UniversityBratislava, Slovak Republic. 2. Department of Heart Failure & Transplantation, The National Institute of Cardiovascular DiseasesBratislava, Slovak Republic. 3. Department of Pharmacology & Pharmacotherapy, Semmelweis UniversityBudapest, Hungary. 4. Institute of CardiologyWarszawa, Poland. 5. Clinic of Heart Surgery, The National Institute of Cardiovascular DiseasesBratislava, Slovak Republic.
Abstract
BACKGROUND: In human failing hearts (HF) of different origin (coronary artery disease-CAD, dilated-DCM, restrictive and hypertrophic cardiomyopathy-OTHER), we investigated the active forms of Ca2+/calmodulin-dependent protein kinase IIδ (p-Thr287-CaMKIIδ, oxMet281/282-CaMKIIδ) and their role in phenotypes of the disease. METHODS AND RESULTS: Although basic diagnostic and clinical markers indicating the attenuated cardiac contractility and remodeling were comparable in HF groups, CaMKIIδ-mediated axis was different. P-Thr287-CaMKIIδ was unaltered in CAD group, whereas it was upregulated in non-ischemic cardiomyopathic groups. No correlation between the upregulated p-Thr287-CaMKIIδ and QT interval prolongation was detected. Unlike in DCM, oxMet281/282-CaMKIIδ did not differ among HF groups. Independently of CaMKIIδ phosphorylation/oxidation, activation of its downstreams-phospholamban and cardiac myosin binding protein-C was significantly downregulated supporting both diminished cardiac lusitropy and inotropy in all hearts. Content of sarcoplasmic reticulum Ca2+-ATPase 2a in all HF was unchanged. Protein phosphatase1β was upregulated in CAD and DCM only, while 2A did not differ among groups. CONCLUSION: This is the first demonstration that the posttranslational activation of CaMKIIδ differs in HF depending on etiology. Lower levels of downstream molecular targets of CaMKIIδ do not correlate with either activation of CaMKIIδ or the expression of major protein phosphatases in the HF. Thus, it is unlikely that these mechanisms exclusively underlie failing of the heart.
BACKGROUND: In human failing hearts (HF) of different origin (coronary artery disease-CAD, dilated-DCM, restrictive and hypertrophic cardiomyopathy-OTHER), we investigated the active forms of Ca2+/calmodulin-dependent protein kinase IIδ (p-Thr287-CaMKIIδ, oxMet281/282-CaMKIIδ) and their role in phenotypes of the disease. METHODS AND RESULTS: Although basic diagnostic and clinical markers indicating the attenuated cardiac contractility and remodeling were comparable in HF groups, CaMKIIδ-mediated axis was different. P-Thr287-CaMKIIδ was unaltered in CAD group, whereas it was upregulated in non-ischemic cardiomyopathic groups. No correlation between the upregulated p-Thr287-CaMKIIδ and QT interval prolongation was detected. Unlike in DCM, oxMet281/282-CaMKIIδ did not differ among HF groups. Independently of CaMKIIδ phosphorylation/oxidation, activation of its downstreams-phospholamban and cardiac myosin binding protein-C was significantly downregulated supporting both diminished cardiac lusitropy and inotropy in all hearts. Content of sarcoplasmic reticulum Ca2+-ATPase 2a in all HF was unchanged. Protein phosphatase1β was upregulated in CAD and DCM only, while 2A did not differ among groups. CONCLUSION: This is the first demonstration that the posttranslational activation of CaMKIIδ differs in HF depending on etiology. Lower levels of downstream molecular targets of CaMKIIδ do not correlate with either activation of CaMKIIδ or the expression of major protein phosphatases in the HF. Thus, it is unlikely that these mechanisms exclusively underlie failing of the heart.
Entities:
Keywords:
Ca2+/calmodulin-dependent protein kinase II; Human heart failure; cardiac myosin binding protein-C; sarcoplasmic reticulum calcium handling
Authors: Teruo Noguchi; Mark Hünlich; Phillip C Camp; Kelly J Begin; Mohamed El-Zaru; Richard Patten; Bruce J Leavitt; Frank P Ittleman; Norman R Alpert; Martin M LeWinter; Peter VanBuren Journal: Circulation Date: 2004-08-09 Impact factor: 29.690
Authors: Paari Dominic Swaminathan; Anil Purohit; Siddarth Soni; Niels Voigt; Madhu V Singh; Alexey V Glukhov; Zhan Gao; B Julie He; Elizabeth D Luczak; Mei-ling A Joiner; William Kutschke; Jinying Yang; J Kevin Donahue; Robert M Weiss; Isabella M Grumbach; Masahiro Ogawa; Peng-Sheng Chen; Igor Efimov; Dobromir Dobrev; Peter J Mohler; Thomas J Hund; Mark E Anderson Journal: J Clin Invest Date: 2011-07-25 Impact factor: 14.808
Authors: Serena Smeazzetto; Andrea Saponaro; Howard S Young; Maria Rosa Moncelli; Gerhard Thiel Journal: PLoS One Date: 2013-01-04 Impact factor: 3.240